Futura Medical PLC (LON:FUM) Ken James, Head of R&D, talks to Proactive London after announcing the recommendation to approve MED3000 in Europe.
This will be the first, clinically proven treatment for erectile dysfunction that promises to be differentiated due to its rapid speed.
Once the certificate is issued, MED3000 may be marketed throughout the EU without the need of a doctor's prescription subject to any national marketing restrictions.
James explains what happens once they get the certificate, 'it will give us freedom to market the product across all European countries, including the UK'.